Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:03:19 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



RepliCel Life Sciences Inc (2)
Symbol RP
Shares Issued 65,001,560
Close 2023-10-16 C$ 0.10
Market Cap C$ 6,500,156
Recent Sedar+ Documents

RepliCel receives final award re: Shiseido arbitration

2023-10-16 19:09 ET - News Release

Subject: RepliCel Life Sciences Inc. - Dissemination Word Document File: '\\swfile\EmailIn\20231016 160533 Attachment REPLICEL News Release regarding Arbitration Decision.docx' 2 | Page CW20995468.2 NEWS RELEASE 1 | Page CW20995468.2 REPLICEL LIFE SCIENCES INC. Suite 900 - 570 Granville Street Vancouver, BC V6C 3P1 Telephone: (604) 248-8730 Fax: (604) 248-8690 RepliCel Life Sciences Announces Arbitration Decision VANCOUVER, BC - October 16, 2023 - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2), ("RepliCel" or the "Company"). On Monday, October 16, 2023, RepliCel received the Final Award related to its ongoing arbitration proceedings with Shiseido Co. Ltd. ("Shiseido"). The Tribunal dismissed RepliCel's claims finding that Shiseido validly terminated the Collaboration and Technology Transfer Agreement dated effective as of July 9, 2013. Management is currently considering the impact of the decision and assessing its options. For more information, please contact: Andrew Schutte, CEO and President info@replicel.com

© 2026 Canjex Publishing Ltd. All rights reserved.